"Physicians' Clinic of Iowa Hematology & Oncology is focused on bringing hope to life for those who entrust us with such a delicate portion of their lives. Our cancer care team is ready to fight cancer using a collaborative team approach, advanced technology, and personal and compassionate service. In addition, we have received the Quality Oncology Practice Initiative (QOPI) certification, awarded for exceptional outpatient care by the American Society of Clinical Oncology. PCI Hematology & Oncology was the first cancer treatment provider in the Cedar Rapids/Iowa City Corridor to receive the three-year certification."

During the past decade, Iowa Blood and Cancer Care conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 12 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 2 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Iowa Blood and Cancer Care" #1 sponsor was "Alliance for Clinical Trials in Oncology" with 14 trials, followed by "Celgene" with 2 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 2 trials sponsored, "NSABP Foundation Inc" with 2 trials sponsored and "Merck Sharp & Dohme LLC" with 2 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Iowa Blood and Cancer Care" #1 collaborator was "National Cancer Institute (NCI)" with 19 trials as a collaborator, "Bristol-Myers Squibb" with 2 trials as a collaborator, "NCIC Clinical Trials Group" with 2 trials as a collaborator, "North Central Cancer Treatment Group" with 2 trials as a collaborator and "SWOG Cancer Research Network" with 2 trials as a collaborator. Other collaborators include 1 different institutions and companies that were collaborators in the rest 11 trials.

According to Clinical.Site data, the most researched conditions in "Iowa Blood and Cancer Care" are "Breast Cancer" (4 trials), "Lung Cancer" (4 trials), "Lymphoma" (3 trials), "Acute Leukemia" (2 trials) and "Multiple Myeloma" (2 trials). Many other conditions were trialed in "Iowa Blood and Cancer Care" in a lesser frequency.

Most popular intervention types in "Iowa Blood and Cancer Care" are "Drug" (17 trials), "Other" (7 trials), "Biological" (5 trials), "Radiation" (3 trials) and "Genetic" (2 trials). Other intervention types were less common.

The name of intervention was led by "placebo" (4 trials), "Bevacizumab" (2 trials), "carboplatin" (2 trials), "cytogenetic analysis" (2 trials) and "docetaxel" (2 trials). Other intervention names were less common.

The vast majority of trials in "Iowa Blood and Cancer Care" are 20 trials for "All" genders, 4 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Iowa Blood and Cancer Care". undefined are not yet recruiting, undefined are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 18 completed trials in Iowa Blood and Cancer Care, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Iowa Blood and Cancer Care, 0 "Phase 1" clinical trials were conducted, 7 "Phase 2" clinical trials and 13 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".